Digital Biomarkers Market Size, Trends, Growth Factors, Regional Segment Revenue Analysis, 2035
6/6/2024Medical Polymers Market Overview
5/30/2024Digital Twin Market OverviewDriven by the increasing adoption of digital twin technologies in the healthcare applications, we anticipate the global digital twins market for healthcare to grow at an annualized rate of 30%, till 2035. The market for digital twins is likely to be worth USD 12.8 billion in 2024.The highest share of the digital twin’s market, in terms of type of digital twin, is captured by process twins; this trend seems unlikely to change in the foreseen future as well. The faster pace of growth can be attributed to the increase in the demand for product digital twins that enhance equipment capabilities and assist manufacturers improving performance throughout the equipment lifecycle.Digital Twin Market SegmentationKey segments of Digital twin market are Distribution by Application Area (Business Optimization, Predictive Maintenance, Production Design and Development, and Others), Type of Twin (Parts Twin, Product Twin, Process Twin, and System Twin), End Users (Aerospace and Defense, Automotive and Transportation, Healthcare, Manufacturing, Retail, Energy and Utilities, Real Estate, IT and Telecommunication, and Others) and Key Geographical Regions (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World).Further, digital twins intended for cardiovascular disorders currently hold the largest share in the market in terms of therapeutic areas targeted by digital twins. Further, the market for such digital twins is anticipated to grow at a CAGR of 41%, during the given period. In terms of type of applications, the highest share of the digital twin’s market is captured by asset / process management; this trend is expected to shift towards personalized treatment in the future. This can be attributed to the fact that personalized biochemical modeling has experienced an emerging trend in this domain and has demonstrated several promising results, including administrating soft tissue behavior in orthopedic surgical interventions.The projected market opportunity is likely to be well distributed among various end users engaged in this domain, with majority of the revenues coming in from the more developed global regions. Key Geographical Regions of Digital twin market are North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World. The highest share currently, in terms of end users, is captured by digital twins’ market for pharmaceutical companies; this trend is likely to remain same in the future. Further, the market for digital twins specifically intended for patients is anticipated to grow at a faster pace, during the period 2024-2035. The faster pace of growth of such digital twins can be attributed to the increasing research activity and growing interest towards personalized medicine and self-modeling digital twins. Further, in terms of geographical regions,North America currently captures the largest share of the global market, and this trend is expected to continue; the market in the aforementioned region is expected to grow at a CAGR of over 29%, till 2035. This is followed by the share represented by Europe and Asia, which are expected to grow at CAGRs of 29.3% and 30.4%, respectively, during 2024-2035.Digital Twin Market Key PlayersKey players in Digital twin market domain are Ansys, Azure, Bosch, Cisco, Dassault, Systèmes, General Electri, IBM, Oracle, Siemens. Further, this market is likely to grow at an annualized rate of 30%, till 2035. In future, the market for digital twins is expected to reach USD 240.3 billion by 2035.Browse Complete Report at: https://www.rootsanalysis.com/reports/digital-twins-market.htmlBrowse More Related Promotions:
5/30/2024Plasmid DNA Manufacturing Market OverviewPlasmid DNA serves as a vector for gene delivery in gene therapy, offering a transformative approach for the treatment of rare, inherited and acquired diseases as well as those previously deemed incurable.The global plasmid DNA manufacturing market size is estimated to grow from USD 102 million in 2023 to USD 539 million by 2035, representing a CAGR of 14.85% during the forecast period 2023-2035.The production of antigens for vaccines, facilitated by plasmid DNA, has revolutionized disease prevention strategies, specifically during the COVID-19 pandemic. Moreover, plasmid DNA has inherent flexibility and reproducibility, which has led to its adaptability in the production of personalized medicine and precision therapies, resulting to a paradigm shift in patient-centric healthcare. Enhanced techniques for gene editing and targeted gene therapy may arise, driven by plasmid-based platforms.With advancements in synthetic biology, plasmid DNA has the potential to enable the construction of intricate genetic circuits, further fueling the development of novel therapeutics. Driven by the growing technological innovation and rising demand for cell and gene therapy products, DNA / RNA vaccines, the plasmid DNA manufacturing market is anticipated to witness a healthy growth in the foreseen future.In recent years, plasmid DNA service providers are focused on widening their capabilities to offer multiple grades of plasmid DNA in order to meet the growing demand across various pharmaceutical applications, including basic research, drug discovery studies, as well as clinical and commercial applications.Plasmid DNA Manufacturing Market SegmentationPlasmid DNA Manufacturing Market segments include Distribution by Scale of Operation (Commercial, Clinical and Preclinical), Application Area (Cell Therapy Manufacturing, Gene Therapy Manufacturing, DNA / RNA Vaccine Development, Viral Vector Manufacturing, and Other Application Areas), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Oncological Disorders, Rare Disorders, and Other Disorders), and Geography (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World).In fact 45% of the players offer both GMP plasmid manufacturing as well as research grade plasmid manufacturing services. 40% of the companies engaged in this domain have the capabilities to operate at all three scale of operation.Leading Key Players in the Plasmid DNA Manufacturing MarketKey players in Plasmid DNA Manufacturing Market are AGC Biologics, Aldevron, Biomay, Catalent Pharma Solutions, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, Thermo Fisher Scientific, and VGXI. Examples of such firms include (in alphabetical order, large and very large firms based in US) AGC Biologics, Ajinomoto Bio-Pharma Services, Aldevron (acquired by Danaher), Catalent Pharma Solutions, Charles River and GenScript ProBio (a Subsidiary of GenScript). This is followed by those capable of operating at preclinical scale which are about 30%.It is worth highlighting that 50% of the acquisition deals in Plasmid DNA Manufacturing Market are inked with the purpose of geographical expansion. Further, portfolio addition as well as expansion were identified as other key drivers. Examples of entire company acquisitions for both geographical consolidation and portfolio expansion, include (in reverse chronological order) the acquisition of e-Zyvec by PolyPlus (February 2022), Nature Technology by Aldevron (January 2022) and Vigene Biosciences by Charles River (May 2021).In order to build a sustainable competitive edge in the market, companies are actively focusing on offering end-to-end plasmid DNA services, from plasmid construction, plasmid design, plasmid engineering to manufacturing process development and optimization services.Browse Complete Report at: https://www.rootsanalysis.com/reports/plasmid-dna-manufacturing-market.htmlBrowse More Related Promotions:-
5/30/2024or
By clicking below, you agree to our terms of service.
New to HackMD? Sign up